CL2007002620A1 - Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto. - Google Patents

Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto.

Info

Publication number
CL2007002620A1
CL2007002620A1 CL200702620A CL2007002620A CL2007002620A1 CL 2007002620 A1 CL2007002620 A1 CL 2007002620A1 CL 200702620 A CL200702620 A CL 200702620A CL 2007002620 A CL2007002620 A CL 2007002620A CL 2007002620 A1 CL2007002620 A1 CL 2007002620A1
Authority
CL
Chile
Prior art keywords
compound
fluor
isotope
understands
kit
Prior art date
Application number
CL200702620A
Other languages
English (en)
Spanish (es)
Inventor
Lehmann Ananth Srinivasan Lutz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2007002620A1 publication Critical patent/CL2007002620A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CL200702620A 2006-09-08 2007-09-10 Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto. CL2007002620A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
CL2007002620A1 true CL2007002620A1 (es) 2008-05-30

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702620A CL2007002620A1 (es) 2006-09-08 2007-09-10 Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto.

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2279759A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2858907A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
EP2717985A4 (en) * 2011-06-09 2015-02-25 Ge Healthcare Ltd DEVICE AND METHOD FOR DISTILLATION
CN108558939B (zh) * 2013-03-15 2021-08-24 癌靶技术有限责任公司 18f-标记的靶向psma的pet成像剂
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
MA49767A (fr) 2017-08-03 2021-05-26 Synthorx Inc Conjugués de cytokine pour le traitement de maladies auto-immunes
US20210238124A1 (en) * 2018-04-20 2021-08-05 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
CA3127689A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
EP4692065A1 (en) 2023-03-31 2026-02-11 Nissan Chemical Corporation Pyrazole compound and harmful organism control agent

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1990003980A1 (en) * 1988-10-14 1990-04-19 Administrators Of The Tulane Educational Fund Therapeutic peptides
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP2000001856A0 (en) 1997-12-24 2000-09-30 Vertex Pharma Prodrugs of aspartyl protease inhibitors.
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
ES2248084T3 (es) * 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US7115766B2 (en) * 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497316B1 (en) 2002-04-09 2006-07-05 Eli Lilly And Company Growth hormone secretagogues
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
JP2009505962A (ja) 2005-07-29 2009-02-12 バイエル・ヘルスケア・エルエルシー 肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Also Published As

Publication number Publication date
EP2063918A2 (en) 2009-06-03
MA30780B1 (fr) 2009-10-01
EP2455105A3 (en) 2012-09-05
IL211033A0 (en) 2011-04-28
CA2858907A1 (en) 2008-03-13
CA2662449A1 (en) 2008-03-13
NO20091428L (no) 2009-06-03
IL211527A0 (en) 2011-05-31
IL211526A0 (en) 2011-05-31
US20080292548A1 (en) 2008-11-27
JP2014028813A (ja) 2014-02-13
JP5603074B2 (ja) 2014-10-08
EP2455105B1 (en) 2016-02-17
KR20090058553A (ko) 2009-06-09
TW200829277A (en) 2008-07-16
AR062726A1 (es) 2008-11-26
PE20080850A1 (es) 2008-09-02
EP2279759A3 (en) 2013-04-17
EP2063918B1 (en) 2014-02-26
CO6150196A2 (es) 2010-04-20
JP2010503618A (ja) 2010-02-04
RU2009112716A (ru) 2010-10-20
EP2289564A3 (en) 2012-11-14
EP2455105A2 (en) 2012-05-23
AU2007294124A1 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
IL197363A0 (en) 2011-08-01
US8557776B2 (en) 2013-10-15
BRPI0716554A2 (pt) 2013-09-24
EP2289564A2 (en) 2011-03-02
MX2009002492A (es) 2009-08-28
WO2008028688A2 (en) 2008-03-13
CR10654A (es) 2009-04-14
TN2009000063A1 (en) 2010-08-19
EP2279759A2 (en) 2011-02-02
JP5722966B2 (ja) 2015-05-27
WO2008028688A3 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
CL2007002620A1 (es) Compuesto marcado con isotopo de fluor; metodo para preparar dicho compuesto; composicion que comprende dicho compuesto; metodo de tomar imagenes de enfermedades que comprende el compuesto antes mencionado; kit que comprende dicho compuesto.
CL2008000224A1 (es) Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos.
PL2545777T3 (pl) Zastosowanie kompozycji izoksazoliny jako środka przeciwpasożytniczego
BRPI0914465A2 (pt) "método para buscar conteúdos multimídia na internet"
CL2007001759A1 (es) Compuesto metformina r-(+) lipoato; mezcla que comprende metformina y acido r-(+) lipoico; composicion farmaceutica que comprende el compuesto; metodo para preparar el compuesto; kit; y uso para tratar la diabetes.
BRPI0817182A2 (pt) Método para purificar um anticorpo e composições
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
BRPI0718782A2 (pt) Agente de benefício que contém partícula de liberação
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0811720A2 (pt) Método e sistema para proporcionar plataforma personalizada para acessar aplicativo na internet através de rede social e programa de computador.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PT2277977T (pt) Composições que contêm olefinas substituídas por flúor
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2007003302A1 (es) Sistema integrado de almacenamiento y entrega para composiciones nutricionales, que comprende un sello penetrable, una tapa y una punta con proyeccion la que se mueve entre los dos costados de dicho sello; metodo de uso de dicho sistema; kit que comp
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
CL2007000938A1 (es) Metodo para la decodificacion de fotogramas de video que comprende la recepcion de una secuencia de video que comprende una variedad de fotogramas de video, la decodificacion de la secuencia de video y la eliminacion de uno o mas fotogramas de video
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
BRPI0816084A2 (pt) Composto de organoenxofre contendo flúor e composição pesticida compreendendo o mesmo
CL2007002672A1 (es) Compuesto de benceno marcado con fluor radiactivo; metodo para preparar dicho compuesto marcado; composicion que comprende dicho compuesto; metodo para diagnostico de enfermedades por imagenes; conjunto de elementos que comprende dicho compuesto; uso
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
BRPI0819660A2 (pt) Método e sistema educacional que inclui pelo menos uma interface de usuário
BRPI0910478A2 (pt) sistema e método para intensificar a visibilidade de um objeto em uma imagem digital
BRPI0815770A2 (pt) Composto de organoenxofre contendo flúor e composição pesticida do mesmo
CL2007002021A1 (es) Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.